← Eichor
Condition: Her2 Gastric Gastroesophageal Junction Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Her2 Gastric Gastroesophageal Junction Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of Fruquintinib Plus Chemotherapy for Postoperative Treatment of HER2-Negative Gastric Cancer With Poor TRG
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06774222Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-posit
Phase N/A · 36 location(s) · Daiichi Sankyo · NCT06846996DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinom
Phase 2/Phase 3 · 12 location(s) · RemeGen Co., Ltd. · NCT06221748At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1
Phase 3 · 1 location(s) · FutureGen Biopharmaceutical (Beijing) Co., Ltd · NCT06177041Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens
Phase 1/Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06572319BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer
Phase 1 · 1 location(s) · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · NCT06773312T-Dxd in Combination With Ramucirumab as HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT05894824Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 2 · 11 location(s) · RemeGen Co., Ltd. · NCT06155383Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative G
Phase 3 · 10 location(s) · Sun Yat-sen University · NCT05918094Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta
Phase 3 · 286 location(s) · AstraZeneca · NCT07431281First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
Phase 2 · 20 location(s) · Qilu Hospital of Shandong University · NCT06730373Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric
Phase 1/Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT07334431Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab Wi
Phase 3 · 1 location(s) · RemeGen Co., Ltd. · NCT07315750Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Te
Phase 1/Phase 2 · 105 location(s) · Boehringer Ingelheim · NCT06324357Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer
Phase 2 · 1 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT05671822mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · 794 location(s) · Alliance for Clinical Trials in Oncology · NCT05677490A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 · 158 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04389632IKS014 in Advanced Solid Tumors That Express HER2
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05872295Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients
Phase 1/Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06650332A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
Phase 3 · 1 location(s) · Astellas Pharma Global Development, Inc. · NCT07673887Phase 2 Trial of KN026+KN046±XELOX in HER2-positive Locally Advanced GC
Phase 2 · 1 location(s) · Peking University · NCT06023758IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Phase 1/Phase 2 · 1 location(s) · Ruijin Hospital · NCT07025889A Study on the Safety and Efficacy of the Combination of Candenizumab, Lenvatinib, and SOX Regimen in the Treatment of H
NA · 1 location(s) · Fujian Medical University · NCT06277024A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic So
Phase 2 · 119 location(s) · Daiichi Sankyo · NCT06330064A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Phase 3 · 249 location(s) · Astellas Pharma Global Development, Inc. · NCT06901531A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treat
Phase 3 · 293 location(s) · AstraZeneca · NCT06764875Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers
Phase N/A · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT07464470SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT06123494
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.